Welcure Drugs & Pharmaceuticals Board of Directors
Get the latest insights into the leadership at Welcure Drugs & Pharmaceuticals. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Altaf Hussain Shah | Managing Director & CFO |
| Mrs. Deepika Krishnan Iyer | Ind. Non-Executive Director |
| Mr. Ashish Abbi | Ind. Non-Executive Director |
| Mr. Suraj Chagan Solanki | Non Exe.Non Ind.Director |
Welcure Drugs & Pharmaceuticals Share price
WELCURE
9.5
0.28 (3.04%)Last updated on 4 Sep, 2025 | 15:49 IST
BUYSELL
Today's High
9.68
Today's Low
9.45
52 Week Low
6.40
52 Week High
15.89
The current prices are delayed, login to your account for live prices
LoginWelcure Drugs & Pharmaceuticals FAQs
The board at Welcure Drugs & Pharmaceuticals consists of experienced professionals, including Mr. Altaf Hussain Shah , Mrs. Deepika Krishnan Iyer , and others, overseeing the company’s strategic and corporate governance.
Directors at Welcure Drugs & Pharmaceuticals are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Altaf Hussain Shah is the current chairman at Welcure Drugs & Pharmaceuticals.
Executive directors at Welcure Drugs & Pharmaceuticals are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Welcure Drugs & Pharmaceuticals adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Welcure Drugs & Pharmaceuticals, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.